ICAM1 and Stroke: In a mouse MCAO stroke model, genetic deletion of ICAM-1 reduces infarct volume, decreases mortality, and improves outcomes 49, although antibody targeted against ICAM-1 (Enlimomab) failed to provide neuroprotection in clinical trial 50.